期刊论文详细信息
Clinical journal of the American Society of Nephrology: CJASN
Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis
Lesley A. Inker3 
[1] and..¶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;**National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland;*William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts;§Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota;¶Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania;‖National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona;†Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, Maryland;††Boston University School of Medicine, Boston, Massachusetts..*William B. Schwartz Division of Nephrology, Tufts Medical Center, Boston, Massachusetts;‡Department of Medicine, University of California-San Francisco, San Francisco, California
关键词: chronic kidney disease;    albuminuria;    glomerular filtration rate;    follow-up studies;    humans;    prostaglandin R2 D-isomerase;    intramolecular oxidoreductases;    kidney failure, chronic;    lipocalins;    renal insufficiency, chronic;    risk factors;    beta 2-microglobulin;   
DOI  :  10.2215/CJN.03660316
学科分类:泌尿医学
来源: American Society of Nephrology
PDF
【 摘 要 】

Background and objectives Serum β-trace protein (BTP) and β-2 microglobulin (B2M) are associated with risk of ESRD and death in the general population and in populations at high risk for these outcomes (GP/HR) and those with CKD, but results differ among studies.Design, setting, participants, & measurements We performed an individual patient-level meta-analysis including three GP/HR studies (n=17,903 participants) and three CKD studies (n=5415). We compared associations, risk prediction, and improvement in reclassification of eGFR using BTP (eGFRBTP) and B2M (eGFRB2M) alone and the average (eGFRavg) of eGFRBTP, eGFRB2M, creatinine (eGFRcr), and cystatin C (eGFRcys), to eGFRcr, eGFRcys, and their combination (eGFRcr-cys) for ESRD (2075 events) and death (7275 events).Results Mean (SD) follow up times for ESRD and mortality for GP/HR and CKD studies were 13 (4), 6.2 (3.2), 14 (5), and 7.5 (3.9) years, respectively. Compared with eGFRcr, eGFRBTP and eGFRB2M improved risk associations and modestly improved prediction for ESRD and death even after adjustment for established risk factors. eGFRavg provided the most consistent improvement in associations and prediction across both outcomes and populations. Assessment of heterogeneity did not yield clinically relevant differences. For ESRD, addition of albuminuria substantially attenuated the improvement in risk prediction and risk classification with novel filtration markers. For mortality, addition of albuminuria did not affect the improvement in risk prediction with the use of novel markers, but lessened improvement in risk classification, especially for the CKD cohort.Conclusions These markers do not provide substantial additional prognostic information to eGFRcr and albuminuria, but may be appropriate in circumstances where eGFRcr is not accurate or albuminuria is not available. Educational efforts to increase measurement of albuminuria in clinical practice may be more cost-effective than measurement of BTP and B2M for improving prognostic information.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO201904266632295ZK.pdf 158KB PDF download
  文献评价指标  
  下载次数:4次 浏览次数:12次